Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
RiverVest
AddedFeb 13, 2024
UpdatedJun 28, 2026
RiverVest

RiverVest

Operating

RiverVest Venture Partners®: A venture capital firm shaping early-stage life science companies for shareholder value.

Location
St. Louis, MO, US
Founded
2000
Firm
Compare
Portfolio
Employees
Website

Investments

Avalyn Pharma
Avalyn Pharma

Total Raised

$272.5M

Rounds

3

Series C$175MSeptember 2023
Series B$35.5MApril 2020
Series A$62MJanuary 2017
OncoResponse
OncoResponse

Total Raised

$130.1M

Rounds

7

Series Unknown$14MMay 2023
Series C$40.6MMarch 2021
Series B$40MSeptember 2018
Spruce Biosciences
Spruce Biosciences
Public

Total Raised

$161.6M

Rounds

4

Post Ipo Equity$53.6MFebruary 2023
Series B$88MFebruary 2020
Venture Med Group
Venture Med Group

Total Raised

$28M

Rounds

6

Convertible NoteJanuary 2023
Convertible NoteNovember 2021
Series B$15MAugust 2017
Bonum Therapeutics
Bonum Therapeutics

Total Raised

$93M

Rounds

1

Series A$93MNovember 2022
Bluejay Therapeutics
Bluejay Therapeutics

Total Raised

$41M

Rounds

1

Series B$41MAugust 2022
Biolinq
Biolinq

Total Raised

$196.3M

Rounds

8

Series B$100MNovember 2021
Wugen
Wugen

Total Raised

$172M

Rounds

2

Series B$172MJuly 2021
Glycomine
Glycomine

Total Raised

$80M

Rounds

3

Series B$35MJune 2021
Sparrow Pharmaceuticals
Sparrow Pharmaceuticals

Total Raised

$51.1M

Rounds

2

Series A$50MMay 2021
Arch Oncology
Arch Oncology

Total Raised

$250.4M

Rounds

5

Series C$105MApril 2021
Series B$50MMarch 2019
SeQure Dx
SeQure Dx

Total Raised

$17.5M

Rounds

1

Series A$17.5MApril 2021
InterVene
InterVene

Total Raised

$20.9M

Rounds

2

Series B$15MJune 2019
Mirum Pharmaceuticals
Mirum Pharmaceuticals
Public

Total Raised

$497M

Rounds

5

Series A$120MNovember 2018
Neuros Medical
Neuros Medical
Public

Total Raised

$113.7M

Rounds

13

Series A$20MAugust 2017
Genoa Pharmaceuticals
Genoa Pharmaceuticals
Acquired

Total Raised

$64.2M

Rounds

2

Series A$62MMay 2017
Adarza BioSystems
Adarza BioSystems

Total Raised

$64.2M

Rounds

9

Series C$17MJanuary 2017